Eisai Presents Groundbreaking Leqembi Data Showing Potential for Early Intervention in Alzheimer's Disease
Revolutionary Data on Leqembi Presented at CTAD 2025
An Overview of the Findings
At the recently held 18th Clinical Trials in Alzheimer's Disease (CTAD) conference in San Diego, Eisai, a partner of BioArctic AB, shared groundbreaking data regarding the treatment of Alzheimer's disease with Leqembi (lecanemab). The study suggests that early intervention with lecanemab could potentially delay the progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's disease by up to 8.3 years, particularly in patients with low amyloid levels who begin treatment at an early stage.
Key Highlights from the Presentations
Among the many discussions, a significant presentation focused on the long-term benefits of lecanemab treatment based on the Clarity AD trial. This analysis highlighted substantial
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.